Novartis AG (Novartis AG) Accounts Payable & Accrued Expense : $5,712 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Novartis AG Accounts Payable & Accrued Expense?

Novartis AG's quarterly accounts payable & accrued expense declined from Sep. 2023 ($19,961 Mil) to Dec. 2023 ($10,463 Mil) and declined from Dec. 2023 ($10,463 Mil) to Mar. 2024 ($5,712 Mil).

Novartis AG's annual accounts payable & accrued expense increased from Dec. 2021 ($11,396 Mil) to Dec. 2022 ($11,435 Mil) but then declined from Dec. 2022 ($11,435 Mil) to Dec. 2023 ($10,463 Mil).

Novartis AG Accounts Payable & Accrued Expense Historical Data

The historical data trend for Novartis AG's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Accounts Payable & Accrued Expense Chart

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

10,976.00

11,627.00

11,396.00

11,435.00

10,463.00

Novartis AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															8,392.00	8,001.00	19,961.00	10,463.00	5,712.00

Novartis AG Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Novartis AG (Novartis AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (OTCPK:NVSEF) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

NVS:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil NVS:Argentina

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.